Furthermore, SIK2 has been identified as a centrosome kinase regulating the G2-M transition, and its depletion or inhibition sensitizes ovarian cancer to paclitaxel-based chemotherapy [10,12]. This evidence concerns the gene SIK2 and ovarian cancer.